Skip to main content

Table 4 Multivariable model of afatinib starting dose and WBRT pre afatinib on PFS in BM+ patients at start of afatinib. The relationship between starting dose, WBRT pre-afatinib and PFS in patients with BM shown in a multivariable model

From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Multivariable analysis Hazard ratio (95% CI) p-value
Brain RT pre-afatinib
 No 1  
 Yes 2.79 (0.93, 8.35) 0.062
Starting dose
 30 mg 1  
 40 mg 0.22 (0.07, 0.67) 0.006